Abatacept for the prevention of GVHD in patients receiving mismatched unrelated transplants: a real-world analysis

Blood Adv. 2023 Aug 22;7(16):4395-4399. doi: 10.1182/bloodadvances.2023010225.

Authors

Sharmila Raghunandan^{1

2}, Lev Gorfinkel³, Michael Graiser⁴, Brandi Bratrude³, Yvonne Suessmuth^{1

2}, Scott Gillespie⁵, Adrianna Lynn Westbrook⁵, Kirsten M Williams^{1

2}, Michelle L Schoettler^{1

2}, Leslie S Kean³, John Horan³, Amelia A Langston⁴, Muna Qayed^{1

2}, Benjamin Watkins^{1

2}

Affiliations

¹ Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, GA.
² Department of Pediatrics, Emory University, Atlanta, GA.
³ Dana-Farber Cancer Institute, Boston Children's Hospital, Boston, MA.
⁴ Winship Cancer Institute, Emory University, Atlanta, GA.
⁵ Pediatric Biostatistics Core, Emory University, Atlanta, GA.

No abstract available

MeSH terms

Abatacept / therapeutic use
Bone Marrow Transplantation
Graft vs Host Disease* / etiology
Graft vs Host Disease* / prevention & control
Hematopoietic Stem Cell Transplantation* / adverse effects
Humans

Substances

Abatacept